https://scholars.lib.ntu.edu.tw/handle/123456789/467859
標題: | 2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance | 作者: | Chien S.-C. Chen P.-S. Huang Y.-H. SUNG-CHUN TANG Li Y.-H. Yeh H.-I. |
公開日期: | 2019 | 卷: | 118 | 期: | 10 | 起(迄)頁: | 1385-1392 | 摘要: | Statin reduces low-density lipoprotein cholesterol and improves clinical outcomes in high risk patients. In general, statin is a safe and well-tolerated medication. However, varieties of adverse effects are reported in some patients and may interfere long-term drug compliance. Statin-associated muscle events and liver function change account for most of these adverse effects. Patients are regarded as statin intolerance if they need to discontinue statin therapy due to these adverse effects. To date, there is no universal standard definition of statin intolerance. But a pragmatic definition of statin intolerance is essential and helpful for clinicians in daily practice. In this article, after expert consensus meetings and literature review, criteria were recommended to identify patients with statin intolerance in Taiwan. The purpose of this statement is to help health care professionals in Taiwan to diagnose and manage individuals who develop muscular and hepatic side effects after statin therapy. ? 2018 Formosan Medical Association |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/467859 | ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2018.11.017 | SDG/關鍵字: | atorvastatin; fluindostatin; hydroxymethylglutaryl coenzyme A reductase inhibitor; lipid; mevinolin; pitavastatin; pravastatin; rosuvastatin; simvastatin; hydroxymethylglutaryl coenzyme A reductase inhibitor; atherosclerosis; chronic liver disease; disease course; drug hypersensitivity; health care personnel; human; liver disease; liver function; muscle disease; patient care; practice guideline; Review; risk factor; Taiwan; treatment planning; blood; chronic disease; complication; consensus; liver disease; muscle disease; toxic hepatitis; Chemical and Drug Induced Liver Injury; Chronic Disease; Consensus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Diseases; Muscular Diseases; Risk Factors; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。